tirzepatide and cardiovascular outcomes of semaglutide for patients with type 2 diabetes in clinical practice Tirzepatide and Cardiovascular Outcomes: A

Canadian researchers warn that side effects of Ozempic, Wegovy and other similar drugs may cause the heart muscles to atrophy, making it more difficult for users to exercise.

If your GLP-1 medication has stopped producing weight loss results, you may be experiencing treatment resistancea common challenge affecting patients on Ozempic and similar drugs

Subjects were randomized to the test arm receiving synthetic semaglutide (Alkem Laboratories Limited) or the reference arm administered with innovator semaglutide (Wegovy, Novo Nordisk) over 24 weeks in a 2:1 ratio

GLP-1 Receptor Agonists and the Eye: Evidence, Mechanisms, and Clinical Guidance A new multidisciplinary expert consensus published in Diabetes, Obesity & Metabolism (2025) brings clarity to a question often raised in clinical practice: Do GLP-1 receptor agonists increase the risk of ocular complications such as diabetic retinopathy or optic neuropathy

Probiotics may be compatible with semaglutide, but timing, strain selection, and individual GI responses matter significantly

CoQ10 is essential for mitochondrial energy production in your muscles